Advanced search
Publication Cover
Acta Cardiologica Volume 77, 2022 - Issue 9
Submit an article Journal homepage
78
Views
1
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Independent prognostic value of left ventricular mass index in patients with light-chain amyloidosis

Hejing Huanga Department of Ultrasound, Second Affiliated Hospital of Naval Medical University (Changzheng Hospital), Shanghai, ChinaCorrespondence[email protected]
,
Haiyan Heb Department of Hematology, The Myeloma & Lymphoma Center, Second Affiliated Hospital of Naval Medical University (Changzheng Hospital), Shanghai, China
,
Yingyi Qinc Department of Health Statistics, Naval Medical University, Shanghai, China
,
Juan Dub Department of Hematology, The Myeloma & Lymphoma Center, Second Affiliated Hospital of Naval Medical University (Changzheng Hospital), Shanghai, ChinaCorrespondence[email protected]
&
Jialin Songa Department of Ultrasound, Second Affiliated Hospital of Naval Medical University (Changzheng Hospital), Shanghai, ChinaCorrespondence[email protected]
Pages 815-821 | Received 12 Apr 2022, Accepted 21 Aug 2022, Published online: 05 Oct 2022

References

  • Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91(2):141–157.
  • Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45–59.
  • Merlini G, Lousada I, Ando Y, et al. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 2016;30(10):1979–1986.
  • Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047–2060.
  • Barros-Gomes S, Williams B, Nhola LF, et al. Prognosis of light chain amyloidosis with preserved LVEF: added value of 2D speckle-tracking echocardiography to the current prognostic staging system. JACC Cardiovasc Imaging. 2017;10(4):398–407.
  • Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39 e14.
  • Quinones MA, Otto CM, Stoddard M, Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography, et al. Doppler Quantification Task Force of the N, Standards Committee of the American Society of E: recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002;15(2):167–184.
  • He H, Liu J, Jiang H, et al. High serum lactate dehydrogenase adds prognostic value to cardiac biomarker staging system for light chain amyloidosis. J Cancer. 2019;10(23):5622–5627.
  • Gertz MA. Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment. Am J Hematol. 2018;93(9):1169–1180.
  • Di Nunzio D, Recupero A, de Gregorio C, et al. Echocardiographic findings in cardiac amyloidosis: inside two-dimensional, doppler, and strain imaging. Curr Cardiol Rep. 2019;21(2):7.
  • Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361(9371):1787–1789.
  • Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440–2445.
  • Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–3757.
  • Siddiqi OK, Sanchorawala V, Ruberg FL. Echocardiography and survival in light chain cardiac amyloidosis: back to basics. Circ Cardiovasc Imaging. 2018;11(5):e007826.
  • Agha AM, Parwani P, Guha A, et al. Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis. Open Heart. 2018;5(2):e000881.
  • Tei C, Dujardin KS, Hodge DO, et al. Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis. J Am Coll Cardiol. 1996;28(3):658–664.
  • Patel AR, Dubrey SW, Mendes LA, et al. Right ventricular dilation in primary amyloidosis: an independent predictor of survival. Am J Cardiol. 1997;80(4):486–492.
  • Milani P, Dispenzieri A, Scott CG, et al. Independent prognostic value of stroke volume index in patients with immunoglobulin light chain amyloidosis. Circ Cardiovasc Imaging. 2018;11(5):e006588.
  • Ardehali H, Qasim A, Cappola T, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J. 2004;147(5):919–923.
  • Cacciapuoti F. The role of echocardiography in the non-invasive diagnosis of cardiac amyloidosis. J Echocardiogr. 2015;13(3):84–89.
  • Rausch K, Scalia GM, Sato K, et al. Left atrial strain imaging differentiates cardiac amyloidosis and hypertensive heart disease. Int J Cardiovasc Imaging. 2021;37(1):81–90.
  • Buss SJ, Emami M, Mereles D, et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol. 2012;60(12):1067–1076.
  • Salinaro F, Meier-Ewert HK, Miller EJ, et al. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017;18(9):1057–1064.
  • Lee Chuy K, Drill E, Yang JC, et al. Incremental value of global longitudinal strain for predicting survival in patients with advanced AL amyloidosis. JACC CardioOncol. 2020;2(2):223–231.
  • Huntjens PR, Zhang KW, Soyama Y, et al. Prognostic utility of echocardiographic atrial and ventricular strain imaging in patients with cardiac amyloidosis. JACC Cardiovasc Imaging. 2021;14(8):1508–1519.
  • Ternacle J, Bodez D, Guellich A, et al. Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9(2):126–138.
  • Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA. 2020;324(1):79–89.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A worldwide pioneer in biotechnology.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.